$490M raisedMergerHealthcare & Life SciencesCompleted
InMed completes merger with Mentari Therapeutics
InMed Pharmaceuticals completed its merger with privately held Mentari Therapeutics, a clinical-stage biotech developing migraine prevention therapies, and renamed itself Mentari Therapeutics. Pre-merger Mentari closed private financings of about $490 million, and its shares converted at roughly 0.20065 combined-company shares each. Trading begins Nov. 9 under ticker MTRI.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →